Phone-VR practice for interviews, talks and group discussions
TL;DR Rehearsely lets nervous students and young hires rehearse placement interviews, presentations and group discussions in a low-cost phone VR viewer, facing virtual panels that react. Colleges and employers buy it as confidence training. A separate clinical tool, used under psychologists for diagnosed social anxiety, comes later and only with a licence.
India's national survey put all anxiety disorders at 3.6% of adults and left 85% of people with common mental disorders untreated[1]. Global surveys put lifetime social anxiety disorder at 4%, usually starting around age 14, with only 18% treated in poorer countries[2].
Among Indian students the numbers are louder but all over the place. Screening studies of medical students report anywhere from about 11% to 46%[3], depending on the scale and the sample.
The cost shows up at placement interviews, vivas and group discussions. Gradual exposure to feared situations is the standard treatment, but you can't exactly book an interview panel for practice, and trained therapists are scarce.
There are two separate products here - and the line between them matters. The launch product is wellness training that does not screen for, diagnose or treat social anxiety. The later clinical tool is a treatment aid used under a registered psychologist. CDSCO's 2026 guidance treats software that manages a disease as a medical device[4], so that one waits for classification and Indian evidence.
A student slides a phone into a cheap viewer and picks a scene, say an interview panel, a classroom talk or a group discussion. Scenes start friendly and get tougher as panellists interrupt, look at their phones or push back. AI drives the virtual people and the app reports on pace, filler words and eye contact.
Sessions last 10–15 minutes, in Hindi and English first. A short wellbeing check at sign-up sends anyone in severe distress to a counsellor or Tele-MANAS instead of practice.
The original idea proposed augmented reality. Every trial I found used virtual reality and AR has no evidence base for this use[5], so I switched the medium and kept the goal.
Users are 17–28-year-olds who dread speaking up but would never call themselves anxious, and framing it as interview practice takes the stigma away. College placement cells and counselling centres pay first, especially in engineering, management and medical colleges. My working assumption is ₹300–800 per student a year, viewers included.
Employers are a second buyer for new-hire training. Later, clinicians could pay a seat fee. One New Zealand VR-therapy platform charges US$69 per clinician a month (about ₹6,700)[6], which Indian practitioners will not match.
A New Zealand trial published in December 2024 gave 126 adults with moderate to severe social anxiety a six-week self-guided programme on phone VR, and symptoms fell sharply against a waitlist[5]. The viewer cost US$29, about ₹2,800[7]. CDSCO's July 2026 software guidance now marks clearly where wellness ends and regulated treatment begins.
I found no figure for VR confidence or exposure practice in India. The adjacent numbers, all from one market research firm and overlapping, put India's VR-in-healthcare market at US$244.9M in 2024, mostly hardware[8], and its mental health apps market at US$497.9M in 2024 (about ₹4,800 Cr)[9]. Neither measures this niche. Count college seats and placement-training budgets instead.
That New Zealand platform delivers VR exposure through a phone and a cheap viewer, with a clinician portal, and positions itself as a supplement to psychologists[7]. An Indian startup uses VR for anxiety relief and ran a pilot with a university campus in Dubai[10]. A US VR-therapy provider pairs VR with clinicians and insurance billing. Nobody sells interview-focused VR practice to Indian placement cells.
| Difficulty | Moderate (46/100) |
| Starting capital | ₹1.54–2.88 Cr |
| Time to launch | 6–9 months |
Convincing scenes that run on cheap phones, AI characters that react sensibly to Indian accents and useful speech feedback all take skilled work. Colleges buy slowly and around the placement calendar. And there's no outcome evidence yet that AI audiences beat scripted ones.
Not for the launch product, which is confidence training. The later clinical tool is a different story.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Don't trust AI to judge anyone's anxiety. The launch product is practice, not treatment, and anyone in distress goes to a counsellor.
Want to work out the AI layer for Rehearsely? Talk to Yash →
Here's what can go south -
I think this is credible as interview and presentation practice, with a licensed clinical tool as a possible second stage. It suits a founder with VR or edtech skills and contacts in placement cells. If you're tempted to sell an anxiety cure to consumers then don't, because that needs evidence and a licence. Prove first that students come back to practise before real interviews.
My estimate is ₹1.54–2.88 Cr, covering scenes, AI characters, viewers and the first college sales. The kit breaks it down.
Not for confidence training. A tool that treats social anxiety is device software, so it needs a CDSCO classification and psychologist supervision before any treatment claim.
Yes, the training version travels well. A clinical version already runs in New Zealand, so check your own regulator before you make any health claim.
The free Rehearsely validation kit has the line-by-line capital breakdown, the effort scoring, the device-software and student-consent checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for colleges, and 5 assumptions to test. Download the kit →
Thinking about building Rehearsely or something close to it? The make-or-break work is landing the first college before placement season and keeping the two products' claims well apart. That's the kind of thing I help founders sort out early. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.